Hepatology International最新文献

筛选
英文 中文
How to apply artificial intelligence (AI) to facilitate and enhance MASH trials. 如何应用人工智能(AI)促进和加强MASH试验。
IF 7.8 2区 医学
Hepatology International Pub Date : 2026-09-16 DOI: 10.1007/s12072-026-11150-z
Daniel Yan Zheng Lim, Wei Qiang Leow, Daniela S Allende, Wai Kay Seto, Terry Cheuk-Fung Yip, George Boon Bee Goh
{"title":"How to apply artificial intelligence (AI) to facilitate and enhance MASH trials.","authors":"Daniel Yan Zheng Lim, Wei Qiang Leow, Daniela S Allende, Wai Kay Seto, Terry Cheuk-Fung Yip, George Boon Bee Goh","doi":"10.1007/s12072-026-11150-z","DOIUrl":"https://doi.org/10.1007/s12072-026-11150-z","url":null,"abstract":"<p><strong>Introduction: </strong>Metabolic dysfunction-associated steatohepatitis (MASH) is one of the most common liver diseases, but thus far only two drugs (resmetirom and semaglutide) have received conditional approval for use. Successful MASH trials are thus highly desired to fill the therapeutic and evidence gap. Concurrently, AI has powered advances in multiple areas of medicine. We consider in this review the potential applications of AI to enhance MASH trials.</p><p><strong>Methods: </strong>We conduct a narrative review of AI uses in MASH, with a focus on current and potential applications in MASH trials.</p><p><strong>Results: </strong>We describe current digital pathology and AI technologies for MASH grading, a mature application where specific models have been qualified by the FDA and EMA for endpoint determination in MASH trials. We also cover the use of contemporary AI risk models to facilitate patient enrollment, and large language models to facilitate patient interactions including recruitment and retention. Finally, we consider lessons from innovative uses of AI in other medical domains, and how current guidelines shape our thinking about the use of AI in MASH trials.</p><p><strong>Conclusion: </strong>AI has made inroads into the world of MASH trials and shows high potential to further enhance their safety, efficacy, and scientific validity.</p>","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":""},"PeriodicalIF":7.8,"publicationDate":"2026-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148982570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Noninvasive surrogate endpoints in MASH trials: current perspectives and challenges. MASH试验中的无创替代终点:当前的观点和挑战。
IF 7.8 2区 医学
Hepatology International Pub Date : 2026-09-13 DOI: 10.1007/s12072-026-11148-7
Hye Won Lee, Luis Antonio Díaz, Vincent Wai-Sun Wong, Wah Kheong Chan
{"title":"Noninvasive surrogate endpoints in MASH trials: current perspectives and challenges.","authors":"Hye Won Lee, Luis Antonio Díaz, Vincent Wai-Sun Wong, Wah Kheong Chan","doi":"10.1007/s12072-026-11148-7","DOIUrl":"https://doi.org/10.1007/s12072-026-11148-7","url":null,"abstract":"<p><strong>Background: </strong>Metabolic dysfunction-associated steatohepatitis (MASH) is a leading cause of cirrhosis and liver-related morbidity. Current regulatory pathways rely on histology and long-term clinical outcomes, but repeated liver biopsy is noninvasive and poorly reproducible; regulators have signaled interest in noninvasive tests (NITs) as surrogate endpoints.</p><p><strong>Methods: </strong>This review synthesizes contemporary regulatory perspectives, the evidentiary framework for biomarker qualification, and the published performance of leading noninvasive tests (vibration-controlled transient elastography [VCTE], magnetic resonance elastography [MRE], and the enhanced liver fibrosis [ELF] test). We summarize diagnostic, prognostic, monitoring and response assessment data from cohort studies, meta-analyses and trial datasets, and outline the analytical and clinical validation steps required for reasonably likely surrogate endpoint (RLSE) qualification.</p><p><strong>Results: </strong>Evidence shows that baseline values and longitudinal changes in liver stiffness measurement (LSM by VCTE and MRE) and ELF correlate with histological stage and predict liver-related events. VCTE offers broad accessibility and a mature outcome linkage; MRE provides superior accuracy and repeatability; ELF supplies a scalable prognostic blood signal. However, variability in measurement, limited trial-level surrogacy data, and low-event rates in pre-cirrhotic cohorts constrain definitive qualification. Composite or tiered strategies and prospective trial datasets linking on-treatment NIT changes to major adverse liver outcomes are needed.</p><p><strong>Conclusions: </strong>NITs show promise as surrogate endpoints for MASH trials, but full qualification as RLSE requires standardized assays, robust prospective evidence that treatment‑induced biomarker changes predict hard clinical outcomes, and close collaboration among academia, industry, and regulators.</p>","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":""},"PeriodicalIF":7.8,"publicationDate":"2026-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148963287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Real-world outcomes of lenvatinib versus sorafenib as the second-line therapy after atezolizumab plus bevacizumab in patients with hepatocellular carcinoma: a large-scale multicenter study in Korea. lenvatinib vs sorafenib作为atezolizumab + bevacizumab治疗肝细胞癌患者后的二线治疗的实际结果:韩国的一项大规模多中心研究
IF 7.8 2区 医学
Hepatology International Pub Date : 2026-09-11 DOI: 10.1007/s12072-026-11142-z
Min Ji Lee, Subin Lim, Jae Yong Shim, Mi Na Kim, DongKyu Kim, Kyu-Pyo Kim, Kang Mo Kim, Baek-Yeol Ryoo, Won-Mook Choi, Hyun-Jeong Kim, Seung-Hoon Lee, Gaeun Kang, Mira Kang, Won Chul Cha, Jung Yong Hong, Woo Kyoung Jeong, Sung Kyung Ju, Jung-Hyun Won, Doik Lee, Jiyoon Ahn, Do Young Kim
{"title":"Real-world outcomes of lenvatinib versus sorafenib as the second-line therapy after atezolizumab plus bevacizumab in patients with hepatocellular carcinoma: a large-scale multicenter study in Korea.","authors":"Min Ji Lee, Subin Lim, Jae Yong Shim, Mi Na Kim, DongKyu Kim, Kyu-Pyo Kim, Kang Mo Kim, Baek-Yeol Ryoo, Won-Mook Choi, Hyun-Jeong Kim, Seung-Hoon Lee, Gaeun Kang, Mira Kang, Won Chul Cha, Jung Yong Hong, Woo Kyoung Jeong, Sung Kyung Ju, Jung-Hyun Won, Doik Lee, Jiyoon Ahn, Do Young Kim","doi":"10.1007/s12072-026-11142-z","DOIUrl":"https://doi.org/10.1007/s12072-026-11142-z","url":null,"abstract":"<p><strong>Introduction: </strong>After first‑line atezolizumab plus bevacizumab (ATE + BEV) in hepatocellular carcinoma (HCC), optimal second‑line (2L) therapy remains unclear. This study compared the real‑world effectiveness and hepatotoxicity of lenvatinib versus sorafenib as 2L treatment after ATE + BEV.</p><p><strong>Methods: </strong>This retrospective, multicenter study used electronic medical record data from the Liver Cancer IN Korea (LINK) database. Patients who received 2L lenvatinib or sorafenib after ATE + BEV were included. The primary endpoint was overall survival (OS). Secondary endpoints included time to treatment discontinuation (TTD), time to next treatment (TTNT), hepatotoxicity, and tumor marker dynamics. Analyses were conducted in the overall cohort, with additional propensity score (PS)-matched analyses performed.</p><p><strong>Results: </strong>A total of 295 patients were included in the analysis (2L lenvatinib, n = 132; 2L sorafenib, n = 163). Median OS was significantly longer with lenvatinib (not reached) than with sorafenib (6.67 months [95% CI 5.32-17.31]; p = 0.001). Lenvatinib also showed significantly longer TTD (5.49 months [3.75-6.04] vs. 1.84 months [1.68-2.20]; p < 0.001) and TTNT (5.72 months [4.07-7.85] vs. 3.06 months [2.56-3.48]; p = 0.001). These findings were generally consistent after PS-matching. Incidence rates of laboratory-based hepatotoxicity were lower with lenvatinib. From 2L initiation to 3 months after 2L therapy, both AFP and PIVKA-II generally declined in both groups.</p><p><strong>Conclusion: </strong>These findings suggest that lenvatinib may be a promising 2L option following ATE + BEV in HCC, as evidenced by improved OS, longer treatment durability, and lower rates of laboratory-based hepatotoxicity compared with sorafenib. However, given the retrospective observational design, further prospective studies are warranted to confirm these findings.</p>","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":""},"PeriodicalIF":7.8,"publicationDate":"2026-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148944748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Antiviral therapies are associated with reduced mortality but under-utilized in patients with viral hepatocellular carcinoma: a multinational REAL-HCC study. 抗病毒治疗与降低死亡率相关,但在病毒性肝细胞癌患者中未得到充分利用:一项跨国REAL-HCC研究。
IF 7.8 2区 医学
Hepatology International Pub Date : 2026-09-11 DOI: 10.1007/s12072-026-11146-9
Taotao Yan, Pei-Chien Tsai, Ming-Lun Yeh, Dae Won Jun, Hidenori Toyoda, Yao-Chun Hsu, Jennifer Leong, Xiaozhong Wang, Xu Qiang, Hiroshi Abe, Takanori Suzuki, Chia-Yen Dai, Jee-Fu Huang, Wan-Long Chuang, Chung-Feng Huang, Yao-Li Chen, Ping-Yi Lin, Satoshi Yasuda, Joanne Kimiko Liu, Mayumi Maeda, Eiichi Ogawa, Cheng-Hao Tseng, Maria Buti, Philip Vutien, Yu Jun Wong, Huy Trinh, Takashi Honda, Haruki Uojima, Masaru Enomoto, Yasuhito Tanaka, Myron Schwartz, Ramsey Cheung, Ming-Lung Yu, Mindie H Nguyen
{"title":"Antiviral therapies are associated with reduced mortality but under-utilized in patients with viral hepatocellular carcinoma: a multinational REAL-HCC study.","authors":"Taotao Yan, Pei-Chien Tsai, Ming-Lun Yeh, Dae Won Jun, Hidenori Toyoda, Yao-Chun Hsu, Jennifer Leong, Xiaozhong Wang, Xu Qiang, Hiroshi Abe, Takanori Suzuki, Chia-Yen Dai, Jee-Fu Huang, Wan-Long Chuang, Chung-Feng Huang, Yao-Li Chen, Ping-Yi Lin, Satoshi Yasuda, Joanne Kimiko Liu, Mayumi Maeda, Eiichi Ogawa, Cheng-Hao Tseng, Maria Buti, Philip Vutien, Yu Jun Wong, Huy Trinh, Takashi Honda, Haruki Uojima, Masaru Enomoto, Yasuhito Tanaka, Myron Schwartz, Ramsey Cheung, Ming-Lung Yu, Mindie H Nguyen","doi":"10.1007/s12072-026-11146-9","DOIUrl":"https://doi.org/10.1007/s12072-026-11146-9","url":null,"abstract":"<p><strong>Background: </strong>Antiviral treatment can reduce mortality of viral hepatocellular carcinoma (HCC), but may be underutilized.</p><p><strong>Methods: </strong>In a multinational real-world consortium of HCC patients with hepatitis B (HBV-HCC) or C (HCV-HCC), we assessed nucleos(t)ide analog treatment rate in HBV-HCC (2007-2023) and direct acting antiviral treatment rate in HCV-HCC (2015-2023).</p><p><strong>Results: </strong>Among 3973 HCC patients (3186 HBV, 647 HCV, 140 HBV/HCV), 49.7% of HBV-HCC and 63.2% of HCV-HCC received antiviral treatment. For HBV, lower treatment rates were observed in female (41.7% vs. 51.8%), older (> 60) (45.3% vs. 54.5%), non-cirrhosis and decompensated cirrhosis (vs. compensates cirrhosis: 41.3% vs. 43.2% vs. 76.7%), and Asia region (37.9% vs. 85.0%) patients; for HCV, lower rates in male (59.0% vs. 72.4%), compensated and decompensated cirrhosis (vs. noncirrhosis: 62.9% vs. 54.0% vs. 73.2%), and non-Asia region (58.2% vs. 69.9%) patients. Child A cirrhosis and Barcelona Clinic Liver Cancer (BCLC) 0/A patients had highest treatment rates followed by Child B and C or BCLC B, C, or D for both HBV (78.6%, 48.3%, 43.8%; 59.9%, 50.9%, 36.7%, 41.0%) and HCV (68.2%, 53.3%, 38.6%; 72.5%, 53.3%, 51.9%, 30.2%), all P<0.001. Factors independently associated with lower treatment rates were: female, age>60, Asia region, noncirrhosis, and BCLC B or C (vs. 0/A) for HBV; male, age>65, Child B or C cirrhosis (vs. noncirrhosis), and BCLC B or C for HCV. Antiviral treatment was independently associated with reduced mortality in both HBV-HCC and HCV-HCC patients.</p><p><strong>Conclusion: </strong>Despite survival benefits, antiviral therapies were substantially underutilized in both HBV-HCC and HCV-HCC, particularly advanced patients.</p>","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":""},"PeriodicalIF":7.8,"publicationDate":"2026-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148955740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Matrix stiffness shapes early transcriptional trajectories during hepatic stellate cell activation. 基质刚度在肝星状细胞激活过程中形成早期转录轨迹。
IF 7.8 2区 医学
Hepatology International Pub Date : 2026-09-01 DOI: 10.1007/s12072-026-11141-0
Kento Inada, Masato Miyoshi, Sei Kakinuma, Keiya Watakabe, Tomohiro Mochida, Taro Shimizu, Jun Tsuchiya, Tsubasa Nobusawa, Shun Kaneko, Fukiko Kawai-Kitahata, Miyako Murakawa, Sayuri Nitta, Mina Nakagawa, Yasuhiro Asahina, Ryuichi Okamoto
{"title":"Matrix stiffness shapes early transcriptional trajectories during hepatic stellate cell activation.","authors":"Kento Inada, Masato Miyoshi, Sei Kakinuma, Keiya Watakabe, Tomohiro Mochida, Taro Shimizu, Jun Tsuchiya, Tsubasa Nobusawa, Shun Kaneko, Fukiko Kawai-Kitahata, Miyako Murakawa, Sayuri Nitta, Mina Nakagawa, Yasuhiro Asahina, Ryuichi Okamoto","doi":"10.1007/s12072-026-11141-0","DOIUrl":"https://doi.org/10.1007/s12072-026-11141-0","url":null,"abstract":"<p><strong>Background: </strong>Matrix stiffness increases during fibrosis and drives hepatic stellate cell (HSC) activation through YAP-dependent mechanotransduction. Although recent studies have revealed HSC heterogeneity beyond classical quiescent and fully activated states, how physiological-range stiffness influences activation trajectories underlying this heterogeneity remains unclear. This study aimed to determine how substrate stiffness shapes the transcriptomic profiles and biases activation trajectories.</p><p><strong>Methods: </strong>We performed time-resolved single-cell RNA sequencing of primary mouse HSCs cultured on stiffness-tunable polydimethylsiloxane (PDMS) substrates (Soft, 0.2 kPa; Hard, 32 kPa), using tissue culture polystyrene (TCPS) as a conventional baseline. In vitro findings were anchored to public in vivo datasets from mouse and human liver injury.</p><p><strong>Results: </strong>Matrix stiffness altered HSC morphology and transcriptional state, with softer substrates promoting a rounder phenotype and reducing the expression of activation markers, particularly during early activation. Pseudotime and RNA velocity analyses also revealed different early trajectories associated with matrix stiffness. Under the soft condition, HSCs exhibited an expanded quiescent-to-initiatory transitional state characterized by Nrf2-related features and regeneration-associated factors, including Hgf and Rspo3. In contrast, the hard condition induced a gene signature, which was upregulated from early stages of HSC activation onward, localized to fibrotic septa in human liver and correlated with cirrhosis severity in an HCV patient cohort.</p><p><strong>Conclusion: </strong>Matrix stiffness shapes early HSC activation trajectories toward transcriptional programs associated with regeneration or fibrosis. These findings support stiffness-controlled culture systems as improved models of HSC activation and provide a framework for regenerative and antifibrotic strategies.</p>","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":""},"PeriodicalIF":7.8,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148880265","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Contemporary epidemiology and real-world management of hepatocellular carcinoma (HCC) in Australia: insights from a prospective Australian National Clinical Quality Registry. 澳大利亚肝细胞癌(HCC)的当代流行病学和现实世界管理:来自前瞻性澳大利亚国家临床质量登记处的见解。
IF 7.8 2区 医学
Hepatology International Pub Date : 2026-08-28 DOI: 10.1007/s12072-026-11144-x
Jonathan Abdelmalak, John S Lubel, Simone Strasser, Usha Kaur Khalsa, Georgia Martin, Wendy Swift, Xuan Wu, Katherine Bateman, Andrew Chan, Avik Majumdar, Marie Sinclair, Anouk Dev, Pohwein Loh, Steven Bollipo, Merlyn Joseph, Leya Nedumannil, Siddharth Sood, Catherine Yu, Stephen Riordan, Donna Zhuang, Edmund Tse, Marnie Wood, Jacinta Holmes, Jessica Howell, Alexander Thompson, Brooke Gaggin, James O'Beirne, William Kemp, Ammar Majeed, Faizah Alam, Myo J Tang, Irene Binu, Namrata Chauhan, Stephanie Elias, Daniel Saitta, Zina Valaydon, Tsz Hong Yiu, Eileen Lam, John R Zalcberg, Stuart K Roberts
{"title":"Contemporary epidemiology and real-world management of hepatocellular carcinoma (HCC) in Australia: insights from a prospective Australian National Clinical Quality Registry.","authors":"Jonathan Abdelmalak, John S Lubel, Simone Strasser, Usha Kaur Khalsa, Georgia Martin, Wendy Swift, Xuan Wu, Katherine Bateman, Andrew Chan, Avik Majumdar, Marie Sinclair, Anouk Dev, Pohwein Loh, Steven Bollipo, Merlyn Joseph, Leya Nedumannil, Siddharth Sood, Catherine Yu, Stephen Riordan, Donna Zhuang, Edmund Tse, Marnie Wood, Jacinta Holmes, Jessica Howell, Alexander Thompson, Brooke Gaggin, James O'Beirne, William Kemp, Ammar Majeed, Faizah Alam, Myo J Tang, Irene Binu, Namrata Chauhan, Stephanie Elias, Daniel Saitta, Zina Valaydon, Tsz Hong Yiu, Eileen Lam, John R Zalcberg, Stuart K Roberts","doi":"10.1007/s12072-026-11144-x","DOIUrl":"https://doi.org/10.1007/s12072-026-11144-x","url":null,"abstract":"<p><strong>Background and aims: </strong>Hepatocellular carcinoma (HCC) is a rapidly increasing healthcare burden in Australia. We aimed to evaluate the contemporary epidemiology, clinical characteristics, and real-world patterns of care for HCC in Australia using a prospective multicentre clinical quality registry.</p><p><strong>Methods: </strong>This interim analysis utilised data from the Upper Gastrointestinal Cancer Registry (UGICR) HCC module, a multicentre clinical quality registry involving 17 major centres across all mainland Australian states. Patients with a new diagnosis of HCC from 1 January 2021 were included. Clinical characteristics and initial treatment modalities were compared between liver transplant centres (LTCs) and non-transplant centres (NTCs).</p><p><strong>Results: </strong>A total of 489 patients were analysed (333 LTC, 156 NTC). The cohort was predominantly male (76.7%) with a median age of 67.0 years. Compared to historical data, a marked shift in etiology was observed, with HCV-related HCC declining to 14.1%, while metabolic dysfunction-associated steatotic liver disease (MASLD) and alcohol-related disease emerged as leading contributors with 61.7% patients identified as affected by steatotic liver disease. Overall, 56.9% of patients presented with early-stage disease (BCLC 0/A). Across the entire cohort of patients with HCC, 42.9% detected after surveillance. In those with BCLC-A disease, LTCs were more likely to utilise initial TACE (36.0% vs. 16.4%; p = 0.021), whereas NTCs favoured upfront ablation. In BCLC-D patients, NTCs relied more heavily on supportive care (66.7% vs. 30.6%; p = 0.019) in contrast to LTC patients who were more likely to receive disease modifying treatment.</p><p><strong>Conclusions: </strong>MASLD is emerging as the leading cause of HCC while surveillance uptake remains suboptimal highlighting the importance of both at-risk MASLD case identification and the development of centralised HCC screening for improving the health of Australians. The significant variations in treatment patterns between LTCs and NTCs require further investigation and may provide insights that could lead to targeted quality improvement initiatives.</p>","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":""},"PeriodicalIF":7.8,"publicationDate":"2026-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148850542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clonal hematopoiesis of indeterminate potential and metabolic dysfunction-associated steatotic liver disease: Korean biopsy cohort. 潜在不确定的克隆造血和代谢功能障碍相关的脂肪变性肝病:韩国活检队列。
IF 7.8 2区 医学
Hepatology International Pub Date : 2026-08-27 DOI: 10.1007/s12072-026-11143-y
Yun Kyu Lee, Hyungtai Sim, Sae Kyung Joo, Heejoon Jang, Dong Hyeon Lee, Jeong Hwan Park, Keon Wook Kang, Murim Choi, Won Kim
{"title":"Clonal hematopoiesis of indeterminate potential and metabolic dysfunction-associated steatotic liver disease: Korean biopsy cohort.","authors":"Yun Kyu Lee, Hyungtai Sim, Sae Kyung Joo, Heejoon Jang, Dong Hyeon Lee, Jeong Hwan Park, Keon Wook Kang, Murim Choi, Won Kim","doi":"10.1007/s12072-026-11143-y","DOIUrl":"https://doi.org/10.1007/s12072-026-11143-y","url":null,"abstract":"<p><strong>Background & aims: </strong>Clonal hematopoiesis of indeterminate potential (CHIP) has emerged as a contributor to age-related diseases; however, its clinical relevance to metabolic liver disease remains to be established. This study investigated the association between CHIP and metabolic dysfunction-associated steatotic liver disease (MASLD) severity in a Korean biopsy cohort.</p><p><strong>Methods: </strong>We conducted a prospective analysis of 486 individuals who underwent liver biopsy and whole genome sequencing between 2014 and 2023. CHIP status was defined by pathogenic somatic mutations in known driver genes with a variant allele frequency ≥2%. Histological assessment was performed using the NASH-CRN scoring system. Logistic regression was used for cross-sectional associations, and Cox proportional hazards models were applied for fibrosis progression outcomes.</p><p><strong>Results: </strong>Among 427 eligible participants (median age 56 years), 37 (8.7%) harbored pathogenic CHIP mutation, predominantly DNMT3A (n=8) and TET2 (n=6). CHIP prevalence did not differ significantly across histological categories: no steatotic liver disease (10.9%), metabolic dysfunction-associated steatotic liver (6.5%), and metabolic dysfunction-associated steatohepatitis (10.9%; p=0.269). No clinical or histological variable was consistently associated with CHIP across definitions in adjusted or unadjusted analyses. Over a median 28-month follow-up, fibrosis progression occurred in 28 of 287 patients with serial assessments; no significant association with CHIP status was observed (HR 0.67, 95% CI 0.16-2.84; p=0.582).</p><p><strong>Conclusions: </strong>In this biopsy-based cohort, CHIP was not significantly associated with hepatic histology severity or fibrosis progression. Given the limited number of CHIP carriers and progression events, clinically meaningful associations cannot be excluded and larger, longer-term longitudinal studies are warranted.</p>","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":""},"PeriodicalIF":7.8,"publicationDate":"2026-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148840258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparative risk of hepatocellular carcinoma and mortality among initiators of GLP-1 receptor agonists versus other glucose-lowering therapies: a target trial emulation. GLP-1受体激动剂启动者与其他降糖疗法的肝细胞癌和死亡率的比较风险:一项目标试验模拟
IF 7.8 2区 医学
Hepatology International Pub Date : 2026-08-12 DOI: 10.1007/s12072-026-11138-9
Jesus Gibran Hernández-Pérez, Omer Abdelgadir, Subin Jang, Deepali K Ernest, Xiaotao Zhang, Dimpy Shah, Arthur S Hong, Jaime P Almandoz, Lindsay G Cowell, Sarah E Messiah, David S Lopez
{"title":"Comparative risk of hepatocellular carcinoma and mortality among initiators of GLP-1 receptor agonists versus other glucose-lowering therapies: a target trial emulation.","authors":"Jesus Gibran Hernández-Pérez, Omer Abdelgadir, Subin Jang, Deepali K Ernest, Xiaotao Zhang, Dimpy Shah, Arthur S Hong, Jaime P Almandoz, Lindsay G Cowell, Sarah E Messiah, David S Lopez","doi":"10.1007/s12072-026-11138-9","DOIUrl":"10.1007/s12072-026-11138-9","url":null,"abstract":"<p><strong>Introduction: </strong>Glucagon-like peptide-1 receptor agonists (GLP-1 RA) may influence pathways involved in hepatocarcinogenesis, but evidence regarding their association with hepatocellular carcinoma (HCC) and mortality risk remains heterogeneous. We evaluated the association between GLP-1 RA initiation and HCC incidence compared with commonly used glucose-lowering medications, with secondary exploratory analyses of all-cause mortality following HCC diagnosis.</p><p><strong>Methods: </strong>We emulated active-comparator, new-user target trials using Patient-Centered Clinical Research Network data from UT Southwestern Medical Center (PCORnet-UTSW; 2010-2025). Adults with T2D initiating GLP-1 RA were compared with initiators of metformin, insulin, sodium-glucose cotransporter-2 inhibitors (SGLT2i), dipeptidyl peptidase-4 inhibitors (DPP4i), and sulfonylureas. The primary outcome was incident HCC; a secondary analysis evaluated all-cause mortality after HCC diagnosis. Five-year risks and risk differences under the intention-to-treat (ITT) approach were estimated using pooled logistic regression with inverse probability of treatment weighting. Per-protocol analyses accounted for treatment adherence using inverse probability of censoring weights.</p><p><strong>Results: </strong>GLP-1 RA initiators had lower five-year HCC risk than comparator groups. Under ITT, risk differences were - 0.37% (95% CI - 0.59 to - 0.08) versus metformin, - 0.52% (95% CI - 0.74 to - 0.35) versus insulin, - 0.37% (95% CI - 0.70 to - 0.06) versus DPP4i, and - 0.39% (95% CI - 0.64 to - 0.13) versus sulfonylureas. Findings were stronger in per-protocol analyses and consistent across subgroups, sensitivity analyses and by individual GLP-1 RA agent. Mortality analyses were limited by small sample sizes but suggested a potential survival benefit.</p><p><strong>Conclusions: </strong>GLP-1 RA initiation was associated with lower HCC risk versus several comparators. Mortality findings were inconclusive and exploratory, warranting confirmation in larger studies.</p>","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":""},"PeriodicalIF":7.8,"publicationDate":"2026-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148722272","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hepatic fibrosis severity assessed by FIB-4 index is independently associated with reduced kidney function in patients with metabolic dysfunction-associated steatotic liver disease: a nationwide multicenter study from Türkiye. 由FIB-4指数评估的肝纤维化严重程度与代谢功能障碍相关脂肪变性肝病患者肾功能下降独立相关:一项来自<s:1> rkiye的全国性多中心研究。
IF 7.8 2区 医学
Hepatology International Pub Date : 2026-08-12 DOI: 10.1007/s12072-026-11139-8
Hilmi Erdem Sumbul, Ali Kirik, Selcuk Yaylaci, Alihan Oral, Sibel Ocak Serin, Kubilay Issever, Nizameddin Koca, Ahmet Aydin, Ismail Demir, Nevzat Gozel, Pinar Yildiz, Oguzhan Sitki Dizdar, Enes Seyda Sahiner, Seyit Uyar, Emin Gemcioglu, Hasan Esat Yucel, Cem Sahin, Hasan Sozel, Osman Ozudogru, Gokhan Tazegul, Melisa Sahin Tekin, Emel Saglam, Begum Seyda Avci, Erdinc Gulumsek, Huseyin Ali Ozturk, Demet Yalcin Kehribar, Hasan Tunca, Elif Duygu Topan, Tuba Taslamacioglu Duman, Abdullah Tanrikulu, Hakan Sivgin, Hikmet Oztop, Muhammet Ozbilen, Necip Nas, Mehmet Selim Mamis, Ozge Kurtkulagi, Kamil Konur, Ismail Kirli, Fatih Kamis, Ozge Kama Basci, Ahmed Bilal Genc, Muzeyyen Eryilmaz, Betül Erismis, Yasin Sahinturk, Nur Duzen Oflas, Erkan Dulkadiroglu, Ayse Kevser Demir, Deniz Cekic, Erkan Cakmak, Hatice Beyazal Polat, Hilal Bektas Uysal, Turkan Pasali Kilit, Sibel Demiral Sezer, Emine Binnetoglu, Esref Arac, Ihsan Solmaz, Hacer Sen, Gulali Aktas, Burcin Meryem Atak Tel, Lale Saka Baraz, Bahri Abayli, Hale Akan, Canan Akkus, Berrin Aksakal, Sami Bahcebasi, Orhan Balikci, Muharrem Bayrak, Omer Faruk Alakus, Ifakat Irem Bicer, Rifat Bozkus, Bilgin Bahadir Basgoz, Fatih Coskun, Cuneyt Cagatay, Feride Caglar, Ulfet Deger, Ali Erol, Aysegul Ertinmaz, Melis Gokgoz, Fatih Ileri, Ugur Can Izlimek, Aynur Kamburoglu, Sanem Kayhan, Yusuf Kimyon, Seref Enes Kocaman, Celalettin Kucuk, Hatice Metin, Oktay Olmuscelik, Erkan Ozdemir, Ensar Ozmen, Hatice Ozge Serin, Ahmet Veli Sanibas, Ece Unal Cetin, Nazif Yalcin, Mehmet Serdar Yildirim, Hasan Esat Yildirim, Huseyin Yildiz, Oguzhan Zengin, Ali Zeynettin, Fatih Atik, Selin Muge Aslan, Nurcan Aslan, Sare Babacan Celikel, Suat Baran Bakan, Bektas Isik, Cisem Yilmaz, Ahmet Gazi Mustan, Cahit Dincer, Yagmur Sena Tosun, Rabia Ulutas, Tugce Nur Yazici, Emrah Yilmaz, Muhammed Rasit Altinisik, Bercem Berent, Hamit Yildiz, Ramazan Azim Okyay
{"title":"Hepatic fibrosis severity assessed by FIB-4 index is independently associated with reduced kidney function in patients with metabolic dysfunction-associated steatotic liver disease: a nationwide multicenter study from Türkiye.","authors":"Hilmi Erdem Sumbul, Ali Kirik, Selcuk Yaylaci, Alihan Oral, Sibel Ocak Serin, Kubilay Issever, Nizameddin Koca, Ahmet Aydin, Ismail Demir, Nevzat Gozel, Pinar Yildiz, Oguzhan Sitki Dizdar, Enes Seyda Sahiner, Seyit Uyar, Emin Gemcioglu, Hasan Esat Yucel, Cem Sahin, Hasan Sozel, Osman Ozudogru, Gokhan Tazegul, Melisa Sahin Tekin, Emel Saglam, Begum Seyda Avci, Erdinc Gulumsek, Huseyin Ali Ozturk, Demet Yalcin Kehribar, Hasan Tunca, Elif Duygu Topan, Tuba Taslamacioglu Duman, Abdullah Tanrikulu, Hakan Sivgin, Hikmet Oztop, Muhammet Ozbilen, Necip Nas, Mehmet Selim Mamis, Ozge Kurtkulagi, Kamil Konur, Ismail Kirli, Fatih Kamis, Ozge Kama Basci, Ahmed Bilal Genc, Muzeyyen Eryilmaz, Betül Erismis, Yasin Sahinturk, Nur Duzen Oflas, Erkan Dulkadiroglu, Ayse Kevser Demir, Deniz Cekic, Erkan Cakmak, Hatice Beyazal Polat, Hilal Bektas Uysal, Turkan Pasali Kilit, Sibel Demiral Sezer, Emine Binnetoglu, Esref Arac, Ihsan Solmaz, Hacer Sen, Gulali Aktas, Burcin Meryem Atak Tel, Lale Saka Baraz, Bahri Abayli, Hale Akan, Canan Akkus, Berrin Aksakal, Sami Bahcebasi, Orhan Balikci, Muharrem Bayrak, Omer Faruk Alakus, Ifakat Irem Bicer, Rifat Bozkus, Bilgin Bahadir Basgoz, Fatih Coskun, Cuneyt Cagatay, Feride Caglar, Ulfet Deger, Ali Erol, Aysegul Ertinmaz, Melis Gokgoz, Fatih Ileri, Ugur Can Izlimek, Aynur Kamburoglu, Sanem Kayhan, Yusuf Kimyon, Seref Enes Kocaman, Celalettin Kucuk, Hatice Metin, Oktay Olmuscelik, Erkan Ozdemir, Ensar Ozmen, Hatice Ozge Serin, Ahmet Veli Sanibas, Ece Unal Cetin, Nazif Yalcin, Mehmet Serdar Yildirim, Hasan Esat Yildirim, Huseyin Yildiz, Oguzhan Zengin, Ali Zeynettin, Fatih Atik, Selin Muge Aslan, Nurcan Aslan, Sare Babacan Celikel, Suat Baran Bakan, Bektas Isik, Cisem Yilmaz, Ahmet Gazi Mustan, Cahit Dincer, Yagmur Sena Tosun, Rabia Ulutas, Tugce Nur Yazici, Emrah Yilmaz, Muhammed Rasit Altinisik, Bercem Berent, Hamit Yildiz, Ramazan Azim Okyay","doi":"10.1007/s12072-026-11139-8","DOIUrl":"10.1007/s12072-026-11139-8","url":null,"abstract":"<p><strong>Background and aims: </strong>Metabolic dysfunction-associated steatotic liver disease (MASLD) is increasingly recognized as a systemic metabolic disorder associated with extrahepatic organ damage, including chronic kidney disease (CKD). The Fibrosis-4 (FIB-4) index is a validated non-invasive tool for estimating hepatic fibrosis severity. This study aimed to investigate whether FIB-4-defined hepatic fibrosis is independently associated with reduced estimated glomerular filtration rate (eGFR) in a large, real-world Turkish MASLD cohort.</p><p><strong>Methods: </strong>This is a cross-sectional analysis of the prospective, nationwide, multicenter DAHUDER MASLD Study, which enrolled patients from 44 internal medicine outpatient clinics across 31 provinces representing all 12 statistical regions of Türkiye. A total of 10,873 MASLD patients were included. MASLD was defined as ultrasonographic hepatic steatosis in the presence of at least one cardiometabolic risk factor. High FIB-4 was defined as ≥ 1.3 for patients aged < 65 years and ≥ 2.0 for those aged ≥ 65 years, per EASL-EASD-EASO 2024 guidelines. eGFR was calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation. Age-stratified multivariate linear regression models were constructed to identify independent predictors of eGFR.</p><p><strong>Results: </strong>High FIB-4 was detected in 11.2% of the patients (n = 1219). Patients with high FIB-4 had significantly lower eGFR compared to those with low FIB-4 (85.37 ± 21.08 vs. 94.18 ± 20.17 mL/min/1.73 m<sup>2</sup>, p < 0.001). FIB-4 score was negatively correlated with eGFR (r =  - 0.149, p < 0.001). In age-stratified multivariate analysis adjusted for diabetes mellitus, hypertension, BMI, sex, SGLT2 inhibitor use, and uric acid, FIB-4 score remained an independent predictor of reduced eGFR in both age groups (< 65 years: B =  - 2.586, 95% CI [- 3.025, - 2.148], p < 0.001; ≥ 65 years: B =  - 1.384, 95% CI [- 2.326, - 0.443], p = 0.004). eGFR decreased progressively across cardiometabolic risk score categories, from approximately 105 mL/min/1.73 m<sup>2</sup> (score 1) to approximately 87 mL/min/1.73 m<sup>2</sup> (score 5). KDIGO-based staging revealed a higher prevalence of advanced CKD stages in the high FIB-4 group (p < 0.001).</p><p><strong>Conclusions: </strong>Hepatic fibrosis severity, as quantified by the FIB-4 index, is independently associated with impaired kidney function in patients with MASLD beyond established cardiometabolic risk factors. These findings support the role of FIB-4 as a simple, cost-effective tool for integrated cardio-hepato-renal risk stratification. Clinicians should systematically monitor renal function in MASLD patients, particularly those with elevated FIB-4 scores.</p>","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":""},"PeriodicalIF":7.8,"publicationDate":"2026-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148721519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
National guideline for hepatitis B elimination in Thailand: a decentralized health system model for expanding diagnosis and treatment. 泰国消除乙型肝炎国家指南:扩大诊断和治疗的分散式卫生系统模式。
IF 7.8 2区 医学
Hepatology International Pub Date : 2026-08-03 DOI: 10.1007/s12072-026-11135-y
Phunchai Charatcharoenwitthaya, Tawesak Tanwandee, Pisit Tangkijvanich, Teerha Piratvisuth, Chatree Jullapetch, Cheewanan Lertpiriyasuwat, Pongtorn Chartpitak
{"title":"National guideline for hepatitis B elimination in Thailand: a decentralized health system model for expanding diagnosis and treatment.","authors":"Phunchai Charatcharoenwitthaya, Tawesak Tanwandee, Pisit Tangkijvanich, Teerha Piratvisuth, Chatree Jullapetch, Cheewanan Lertpiriyasuwat, Pongtorn Chartpitak","doi":"10.1007/s12072-026-11135-y","DOIUrl":"https://doi.org/10.1007/s12072-026-11135-y","url":null,"abstract":"<p><p>Despite sustained universal infant hepatitis B vaccination, chronic hepatitis B (CHB) remains an important cause of cirrhosis and hepatocellular carcinoma in Thailand, particularly among adults born before vaccine implementation. This article summarizes the 2026 National Guideline on Elimination of Viral Hepatitis B in Thailand and presents a health-system framework for addressing the remaining disease burden. The guideline was developed by a multidisciplinary expert panel using evidence from international recommendations, peer-reviewed literature, national epidemiological data, implementation studies, and health economic analyses. The recommendations were formulated using the GRADE framework and adapted for implementation within Thailand's Universal Health Coverage system. The national strategy prioritizes birth-cohort HBsAg screening for adults born before 1992, simplified evidence-based treatment eligibility incorporating non-invasive fibrosis assessment and virological criteria, and first-line use of high genetic-barrier nucleos(t)ide analogs. Prevention of mother-to-child transmission prioritizes HBV DNA-guided antiviral prophylaxis, with simplified implementation pathways reserved for settings with substantial diagnostic constraints. Long-term care emphasizes structured monitoring, appropriate specialist referral, conservative treatment discontinuation criteria, defined retreatment thresholds, and risk-based semiannual ultrasound surveillance for hepatocellular carcinoma. Integration with antenatal services, HIV programs, and primary care facilities supports decentralized delivery and continuity of care. Thailand's 2026 hepatitis B guideline operationalizes evidence-based CHB management within a publicly financed decentralized health system and provides a scalable model for expanding hepatitis B diagnosis and treatment in endemic settings.</p>","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":""},"PeriodicalIF":7.8,"publicationDate":"2026-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148669420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书